6533b82dfe1ef96bd1291566
RESEARCH PRODUCT
Anti-hypertensive effects of Rosuvastatin are associated with decreased inflammation and oxidative stress markers in hypertensive rats
Jean-claude GuillandClaudia KorandjiLaurence DuvillardPierre SicardBenjamin LauzierAnabelle Segueira-le GrandStéphanie DelemasureYves CottinLuc RochetteCatherine Vergely Marianne Zellersubject
MaleAntioxidantmedicine.medical_treatmentBlood Pressure030204 cardiovascular system & hematologymedicine.disease_causeBiochemistryRats Inbred WKYchemistry.chemical_compound0302 clinical medicineRats Inbred SHR[SDV.IDA]Life Sciences [q-bio]/Food engineeringRosuvastatin CalciumComputingMilieux_MISCELLANEOUSchemistry.chemical_classification0303 health sciencesSulfonamidesGeneral Medicine3. Good healthNAD(P)H oxidasecardiovascular systemmedicine.symptommedicine.drugmedicine.medical_specialtyhypertensionleukocytesInflammationArgininestatins03 medical and health sciences[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemInternal medicinemedicineAnimalsRosuvastatin[SPI.GPROC]Engineering Sciences [physics]/Chemical and Process Engineeringcardiovascular diseasesAntihypertensive Agents030304 developmental biologyInflammationReactive oxygen speciesCholesterolNAD(P)H oxidaseNADPH OxidasescytokinesRatsFluorobenzenesOxidative StressEndocrinologyBlood pressurePyrimidineschemistryInterleukin-4Hydroxymethylglutaryl-CoA Reductase InhibitorsReactive Oxygen SpeciesOxidative stressdescription
International audience; Among their pleiotropic effects, statins exert antioxidant and anti-inflammatory properties. The aim of this study was to evaluate in normotensive (WKY) and in spontaneously hypertensive rats (SHR) the effect of rosuvastatin (ROSU) treatment on (1) plasma inflammation markers and endogenous NO synthase inhibitor (ADMA) levels, (2) reactive oxygen species (ROS) generated by circulating leukocytes and (3) vascular oxidative stress and tissue inflammation markers. Plasma cytokines were higher in SHR than in WKY, except for IL-4, which was lower in SHR than in WKY. SHR monocytes exhibited higher production of ROS than did WKY monocytes. In the experimental conditions, ROSU did not modify plasma cholesterol levels in SHR but attenuated the increase in systolic blood pressure. In SHR only, ROSU lessened pro-inflammatory cytokines and ADMA levels, increased IL-4 and reduced ROS production in circulating monocytes. These results demonstrate the beneficial effects of ROSU in SHR, independently of any lowering of cholesterol levels.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2009-07-07 |